Richmond Pharmacology Ltd

General information

Founded in 2001 Richmond Pharmacology is led by its three founding directors Dr Jorg Taubel, CEO; Dr Ulrike Lorch, Medical Director and Dr Radivoj Arezina, Research Director whose experience has been gained in more than 500 clinical trials.

Specialist services:

* Early phase adaptive studies including First-In-Human
* Cardiac Safety/Intensive ECG/Thorough QT studies
* Ethnic Bridging studies
* Early phase patient studies (therapeutic and non-therapeutic).

Full service:

* Consultancy and Expert Advice
* Protocol Writing & CRF Design
* Regulatory and Ethics Committee Applications
* Healthy Volunteer/Patient Recruitment for Phase I-IV
* Clinical Conduct, Pharmacy services
* Safety Laboratory and Bioanalytical services

Our Business Ethos

Our business ethos is unique: Our revenues serve the National Health Service and St George’s University of London, fund basic research, support charities or otherwise are reinvested in the business. Our business is sustainable, adaptive to change and is led by the same specialists who founded the business more than ten years ago.

Our Sponsors

All our sponsors are preferred clients. Richmond Pharmacology’s interaction with its sponsors is personal and truly strategic, generating enhanced value for drug developers and investors.

Our Work

Our work is closely supervised throughout by the same senior specialists sponsors meet during the first consultation or bid defence. Our services span strategic consultancy and concept development through to final reporting, utilising our many years of experience and leading to successful clinical trials with meaningful results.